Molecular and clinicopathological markers of prognosis in breast cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 5, 2013, Pages 481-498

  Boyle, David P ^a   McCourt, Clare M ^a   Matchett, Kyle B ^a   Salto Tellez, Manuel ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

breast cancer; gene expression; heterogeneity; immunohistochemistry; metabolomics; mutation analysis; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CLAUDIN; CYTOKERATIN 5; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICRORNA 9; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; RNA; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UROKINASE; UVOMORULIN;

AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; METABOLOMICS; MICROMETASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879329235     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.29     Document Type: Review

References (137)

1. Ellis IO, Schnitt SJ, Sastre-Garau X. Tumours of the breast. In: Pathology and Genetics Tumours of the Breast and Female Genital Organs. Tavassoéli FA, Devilee P (Eds), IARC, Lyon, France, 9-41 (2003).
2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380(9855), 1778-1786 (2012).
3. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 72(23), 6097-6101 (2012).
4. Harris L, Fritsche H, Mennel R et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25(33), 5287-5312 (2007).
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005).
6. Ribeiro-Silva A, Zhang H, Jeffrey SS. RNA extraction from ten year old formalin-fixed paraffin-embedded breast cancer samples: a comparison of column purification and magnetic bead-based technologies. BMC Mol. Biol. 8, 118 (2007).
7. De Marzo AM, Fedor HH, Gage WR, Rubin MA. Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum. Pathol. 33(7), 756-760 (2002).
8. Macabeo-Ong M, Ginzinger DG, Dekker N et al. Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses. Mod. Pathol. 15(9), 979-987 (2002).
9. Tbakhi A, Totos G, Pettay JD, Myles J, Tubbs RR. The effect of fixation on detection of B-cell clonality by polymerase chain reaction. Mod. Pathol. 12(3), 272-278 (1999).
10. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63(1), 181-187 (1989).
11. de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 361(7), 653-663 (2009).
12. Hansen NM, Grube B, Ye X et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J. Clin. Oncol. 27(28), 4679-4684 (2009).
13. Rutledge H, Davis J, Chiu R et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection. Mod. Pathol. 18(6), 762-768 (2005).
14. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6), 569-575 (2011).
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5), 403-410 (1991).
16. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer. 11(3), 359-377 (1957).
17. Dalton LW, Page DL, Dupont WD. Histologic grading of breast carcinoma. A reproducibility study. Cancer 73(11), 2765-2770 (1994).
18. Boiesen P, Bendahl PO, Anagnostaki L et al. Histologic grading in breast cancer-reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol. 39(1), 41-45 (2000).
19. Rakha EA, Lee AH, Evans AJ et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J. Clin. Oncol. 28(1), 99-104 (2010).
20. Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 21(3), 289-295 (2012).
21. Ellis IO, Coleman D, Wells C et al. Impact of a national external quality assessment scheme for breast pathology in the UK. J. Clin. Pathol. 59(2), 138-145 (2006).
22. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am. J. Clin. Pathol. 123(1), 21-27 (2005).
23. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(16), 2784-2795 (2010).
24. Badve SS, Baehner FL, Gray RP et al. Estrogen-and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J. Clin. Oncol. 26(15), 2473-2481 (2008).
25. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int. J. Cancer 122(5), 1089-1094 (2008).
26. Davies C, Pan H, Godwin J et al.; for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptorpositive breast cancer: ATLAS, a randomised trial. Lancet doi:10.1016/S0140-6736(12)61963-1(2012) (Epub ahead of print).
27. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 102(9), 627-637 (2010).
28. Roka S, Rudas M, Taucher S et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur. J. Surg. Oncol. 30(3), 243-247 (2004).
29. Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur. J. Cancer 39(5), 622-630 (2003).
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
31. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3(4), 237-252 (1998).
32. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 8(1), 103-112 (1990).
33. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 24(19), 3032-3038 (2006).
34. Wolff AC, Hammond ME, Schwartz JN et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
35. Liu YH, Xu FP, Rao JY et al. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer. Am. J. Clin. Pathol. 132(1), 74-79 (2009).
36. Salto-Tellez M, Yau EX, Yan B, Fox SB. Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. Arch. Pathol. Lab. Med. 135(6), 693-695 (2011).
37. Heredia NJ, Belgrader P, Wang S et al. Droplet Digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples. Methods 59(1), S20-S23 (2013).
38. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N. Engl. J. Med. 364(4), 340-350 (2011).
39. Dowsett M, Nielsen TO, A'Hern R et al.; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 103(22), 1656-1664 (2011).
40. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M; South Sweden Breast Cancer Group. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod. Pathol. 23(2), 251-259 (2010).
41. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98(4), 262-272 (2006).
42. Viale G, Regan MM, Mastropasqua MG et al.; International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J. Natl Cancer Inst. 100(3), 207-212 (2008).
43. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33(11), 2007-2017 (2012).
44. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Ann. Oncol. 14(3), 428-432 (2003).
45. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1(3), 233-240 (2001).
46. Rohan TE, Li SQ, Hartwick R, Kandel RA. p53 alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol. Biomarkers Prev. 15(7), 1316-1323 (2006).
47. Olivier M, Langerød A, Carrieri P et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin. Cancer Res. 12(4), 1157-1167 (2006).
48. Jänicke F, Prechtl A, Thomssen C et al.; German N0 Study Group. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst. 93(12), 913-920 (2001).
49. Harbeck N, Schmitt M, Kates RE et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin. Breast Cancer 3(3), 196-200 (2002).
50. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19(4), 980-991 (2001).
51. Hajage D, de Rycke Y, Bollet M et al. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement. PLoS ONE 6(11), e27446 (2011).
52. Yao-Lung K, Dar-Ren C, Tsai-Wang C. Accuracy validation of Adjuvant! Online in Taiwanese breast cancer patients-a 10-year analysis. BMC Med. Inform. Decis. Mak. 12, 108 (2012).
53. Blamey RW, Pinder SE, Ball GR et al. Reading the prognosis of the individual with breast cancer. Eur. J. Cancer 43(10), 1545-1547 (2007).
54. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002).
55. Edén P, Ritz C, Rose C, Fernö M, Peterson C. 'Good Old' clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur. J. Cancer 40(12), 1837-1841 (2004).
56. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29(32), 4273-4278 (2011).
57. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
58. Curtis C, Shah SP, Chin SF et al.; METABRIC Group. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486(7403), 346-352 (2012).
59. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12(5), R68 (2010).
60. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 26(1), 1-10 (2008).
61. Blows FM, Driver KE, Schmidt MK et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7(5), e1000279 (2010).
62. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736-1747 (2011).
63. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101(10), 736-750 (2009).
64. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750-2767 (2011).
65. Metzger-Filho O, Tutt A, de Azambuja E et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30(15), 1879-1887 (2012).
66. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res. 14(16), 5158-5165 (2008).
67. Bartley AN, Ross DW. Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch. Pathol. Lab. Med. 126(4), 456-458 (2002).
68. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10(16), 5367-5374 (2004).
69. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14(5), 1368-1376 (2008).
70. Choi YL, Oh E, Park S et al. Triplenegative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer 10, 507 (2010).
71. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
72. Banneau G, Guedj M, MacGrogan G et al. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res. 12(4), R63 (2010).
73. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 52(1), 3-10 (2008).
74. Voduc D, Cheang MCU, Prat A et al. The other triple-negative breast cancer: immunohistochemical and clinicopathologic characterization of the claudin-low subtype. J. Clin. Oncol. 29(Abstr 1129), (2011).
75. Polyak K. Heterogeneity in breast cancer. J. Clin. Invest. 121(10), 3786-3788 (2011).
76. Paik S. Is gene array testing to be considered routine now? Breast 20(Suppl. 3), S87-S91 (2011).
77. Kim C, Paik S. Gene-expression based prognostic assays for breast cancer. Nat. Rev. Clin. Oncol. 7(6), 340-347 (2010).
78. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
79. Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol. Oncol. 1(3), 246-251 (2007).
80. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008).
81. Bogaerts J, Cardoso F, Buyse M et al.; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol. 3(10), 540-551 (2006).
82. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
83. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
84. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10(4), R65 (2008).
85. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355(6), 560-569 (2006).
86. Shapiro IM, Cheng AW, Flytzanis NC et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 7(8), p.e1002218 (2011).
87. Ma XJ, Salunga R, Dahiya S et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res. 14(9), 2601-2608 (2008).
88. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expressionbased prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24(11), 1665-1671 (2006).
89. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin. Biochem. Rev. 32(4), 177-195 (2011).
90. Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-generation sequencing in breast cancer: first take home messages. Curr. Opin. Oncol. 24(6), 597-604 (2012).
91. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10(1), 57-63 (2009).
92. Galardi F, Oakman C, Truglia MC et al. Inter-and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast 21(3), 336-342 (2012).
93. Seol H, Lee HJ, Choi Y et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 25(7), 938-948 (2012).
94. Barry WT, Kernagis DN, Dressman HK et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J. Clin. Oncol. 28(13), 2198-2206 (2010).
95. Shah SP, Roth A, Goya R et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403), 395-399 (2012).
96. Navin N, Kendall J, Troge J et al. Tumour evolution inferred by single-cell sequencing. Nature 472(7341), 90-94 (2011).
97. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28(1), 92-98 (2010).
98. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol. 11(10), 1936-1942 (1993).
99. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989).
100. Tamaichi H, Sato M, Porter AC, Shimizu T, Mizutani S, Takagi M. ATM dependent regulation of Topoisomerase II ? expression and sensitivity to Topoisomerase II inhibitor. Cancer. Sci. 104(2), 178-184 (2012).
101. Callagy G, Pharoah P, Chin SF et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J. Pathol. 205(3), 388-396 (2005).
102. Fountzilas G, Christodoulou C, Bobos M et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J. Transl. Med. 10, 212 (2012).
103. Milde-Langosch K, Karn T, Müller V et al. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res. Treat. 137(1), 57-67 (2013).
104. Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front. Immunol. 3, 175 (2012).
105. Panse J, Friedrichs K, Marx A et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br. J. Cancer 99(6), 930-938 (2008).
106. Razis E, Kalogeras KT, Kotoula V et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin. Breast Cancer 12(3), 183-193 (2012).
107. Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann. Oncol. 23(Suppl. 6), vi19-vi22 (2012).
108. Kim ST, Jeong H, Woo OH et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am. J. Clin. Oncol. PMID:22495453 (2012) (Epub ahead of print).
109. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod. Pathol. 21(12), 1527-1532 (2008).
110. Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 52(1), 73-81 (2013).
111. Huang Y, Wang FM, Wang T et al. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion 86(4), 329-337 (2012).
112. Stein R, Mattes MJ, Cardillo TM et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13(18Pt 2), 5556s-5563s (2007).
113. Choi JW, Kim Y, Lee JH, Kim YS. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. Int. J. Urol. 20(2), 251-255(2012).
114. Tian B, Zhang Y, Li N, Liu X, Dong J. CD74: a potential novel target for triple-negative breast cancer. Tumour Biol. 33(6), 2273-2277 (2012).
115. Greenwood C, Metodieva G, Al-Janabi K et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J. Proteomics 75(10), 3031-3040 (2012).
116. Badve S, Nakshatri H. Breast-cancer stem cells-beyond semantics. Lancet Oncol. 13(1), e43-e48 (2012).
117. Ohi Y, Umekita Y, Yoshioka T et al. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology 59(4), 776-780 (2011).
118. Schwartz T, Stark A, Pang J et al. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 119(3), 488-494 (2013).
119. De Brot M, Rocha RM, Soares FA, Gobbi H. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 44(4), 303-312 (2012).
120. Albain KS, Barlow WE, Shak S et al.; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55-65 (2010).
121. Filipits M, Rudas M, Jakesz R et al.; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17(18), 6012-6020 (2011).
122. Chen D, Sun Y, Wei Y et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 18(10), 1511-1517 (2012).
123. Ma L, Young J, Prabhala H et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12(3), 247-256 (2010).
124. Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat. Rev. Cancer 9(4), 253-264 (2009).
125. Bathen TF, Sitter B, Sjøbakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res. 70(17), 6692-6696 (2010).
126. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 19(1), 30-40 (2006).
127. Chan EC, Koh PK, Mal M et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8(1), 352-361 (2009).
128. Sitter B, Bathen TF, Singstad TE et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 23(4), 424-431 (2010).
129. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009).
130. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
131. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA 100(18), 10393-10398 (2003).
132. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 6, 289-297 (2012).
133. Bevilacqua JL, Kattan MW, Fey JV, Cody HS 3rd, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J. Clin. Oncol. 25(24), 3670-3679 (2007).
134. Van Zee KJ, Manasseh DM, Bevilacqua JL et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 10(10), 1140-1151 (2003).
135. Rudloff U, Jacks LM, Goldberg JI et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J. Clin. Oncol. 28(23), 3762-3769 (2010).
136. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25(28), 4414-4422 (2007).
137. Albert JM, Liu DD, Shen Y et al. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J. Clin. Oncol. 30(23), 2837-2843 (2012).